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The metalloproteinase matrilysin proteolytically generates active
soluble Fas ligand and potentiates epithelial cell apoptosis
William C. Powell*†‡, Barbara Fingleton*‡, Carole L. Wilson*§, Mark Boothby¶
and Lynn M. Matrisian*
Background: The Fas ligand/Fas receptor (FasL/Fas) system is an important
mediator of apoptosis in the immune system where the juxtaposition of cells
expressing the cell-surface ligand induces the apoptotic pathway in Fas-
expressing lymphocytes. The FasL/Fas system has also been shown to be
involved in apoptosis in epithelial tissues, including the involuting rodent
prostate. FasL can be shed through the action of an hitherto unidentified
metalloproteinase to yield soluble FasL (sFasL), although the biological activity
of sFasL has been disputed.
Results: Here we report that the matrix metalloproteinase matrilysin can
process recombinant and cell-associated FasL to sFasL, and that matrilysin-
generated sFasL was effective at inducing apoptosis in a target epithelial cell
population. In the involuting mouse prostate, FasL and matrilysin colocalized
to the cell surface in a restricted population of epithelial cells. Mice deficient
in matrilysin demonstrated a 67% reduction in the apoptotic index in the
involuting prostate compared with wild-type animals, implicating matrilysin in
this FasL-mediated process.
Conclusions: These results show that a functional form of sFasL was
generated by the action of the metalloproteinase matrilysin, and suggest that
matrilysin cleavage of FasL is an important mediator of epithelial cell apoptosis.
Background
The Fas ligand/Fas receptor (FasL/Fas) system was ini-
tially identified as an important mediator of apoptosis in
the immune system, in which interaction with cells
expressing cell-surface FasL induces the apoptotic
pathway in Fas-expressing lymphocytes [1]. A number of
studies have identified non-lymphoid tissues expressing
both Fas and FasL [2,3], however, and it has been sug-
gested that precise spatial and temporal regulation of the
FasL–Fas interaction controls remodeling in these tissues.
Recently, the FasL/Fas system has been implicated in
prostate involution. The withdrawal of androgen by physi-
cal or chemical castration initiates the involution of the
rodent prostate. There is an overall reduction in organ
size, apoptosis of the prostate epithelial cells, and a change
in the composition of the gland to contain primarily con-
nective tissue components [4]. Fas levels have been
reported to increase in the mouse prostate following cas-
tration, and in lpr mice deficient in functional Fas, andro-
gen withdrawal is followed by inhibition of involution and
failure to induce DNA fragmentation [5]. In the involuting
rat ventral prostate, both Fas and FasL were reported to be
induced following castration and to decline after the
process was completed [6,7]. The requirement for
FasL–Fas interactions in involuting prostate epithelial cells
presents a topological problem regarding the accessibility
of a cell-surface ligand to a receptor when both are posi-
tioned on the apical surface of cells that are anchored to a
basement membrane. A potential solution to this conun-
drum is that FasL can be processed to a soluble form
(sFasL) by an as-yet-unidentified metalloproteinase [8,9].
Both the transmembrane and soluble forms of human
FasL have been shown to be active in inducing apoptosis
in lymphoid cell targets. Under the same conditions,
however, murine sFasL has been reported to be nonfunc-
tional [10–12]. Thus, the mechanism of Fas stimulation in
the involuting rodent prostate is unclear.
We have previously reported that the matrix-degrading
metalloproteinase matrilysin (MMP-7, PUMP-1, EC
3.4.24.23) is strongly induced in the epithelium of the rat
ventral prostate during involution [13]. Matrilysin is dis-
tinct from the other known MMP family members in that
it is preferentially expressed by cells of glandular epithe-
lium rather than in connective tissues [14]. In addition to
its activity on basement membrane and extracellular
matrix components, matrilysin has been reported to cleave
a variety of secreted and cell-surface proteins [14]. These
cell-surface substrates include the transmembrane precur-
sor to tumor necrosis factor-α (TNF-α), a member of the
same protein family as FasL. Cleavage of the TNF-α pre-
cursor by matrilysin and several other metalloproteinases
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can result in the release of active ligand from the cell
surface [15]. Although the processing of both TNF-α and
FasL is efficiently blocked by synthetic MMP inhibitors,
it is not affected by the endogenous regulators of MMP
activity, the tissue inhibitors of metalloproteinases
TIMP-1 and TIMP-2 [16,17]. This suggested that the rel-
evant ‘sheddase’ is a metalloproteinase of a different sub-
family. In fact, the TNF-α converting enzyme, TACE,
was identified as a member of the ADAM (a disintegrin
and metalloproteinase) family of metalloproteinases, a
group distinct from the MMPs [18,19]. Within the MMP
family, however, matrilysin is the only known member
that lacks the hemopexin domain thought to be important
in interactions with TIMPs and is thus believed to be less
sensitive to the inhibitory action of these proteins [20].
These observations, combined with the requirement for
Fas in prostate involution, led us to design experiments to
determine if FasL is a matrilysin substrate and if
matrilysin is functionally involved in prostate involution.
Our results indicate that matrilysin can proteolytically
process murine FasL to an active soluble form and that
tissue involution requiring FasL-mediated apoptosis is
attenuated by the lack of this enzyme.
Results
FasL is a direct substrate of matrilysin
To determine if FasL is a matrilysin substrate, purified
recombinant human matrilysin was activated and incu-
bated with FLAG-tagged recombinant human FasL
(rhFasL). Intact and cleaved FasL was detected by
western blot analysis using an anti-FLAG antibody.
Matrilysin, at an approximately 1:1 molar ratio to rhFasL,
efficiently cleaved > 90% of rhFasL in 30 minutes
(Figure 1a). Cleavage was completely inhibited in the pres-
ence of the synthetic MMP inhibitor Batimastat
(Figure 1a). To determine if a similar cleavage event
occurred with FasL in its native conformation on the cell
surface, murine splenocytes were treated with con-
canavalin A and interleukin-2 for 8 hours to induce lym-
phocyte FasL expression [10]. The FasL-expressing
splenocytes were incubated with activated recombinant
matrilysin for 6 hours and the conditioned medium was
analyzed for FasL by western blotting. Matrilysin treat-
ment increased the amount of the 26 kDa soluble form of
FasL in conditioned medium in a dose-dependent manner
that was inhibited by the addition of 5 µM Batimastat
(Figure 1b and data not shown). Splenocytes isolated from
mice homozygous for the gld mutation, an inactivating
point mutation in the FasL gene that abrogates FasL inter-
action with the Fas receptor [21], were cleaved similarly,
indicating that the mutation in FasL in these cells does not
affect its ability to be proteolytically processed.
sFasL induces apoptosis in epithelial cells
The sFasL released by matrilysin cleavage was assayed for
apoptosis-inducing ability using human embryonic kidney
293 cells as indicators. The 293 cells represent a non-tumor
epithelial cell line that expresses Fas and is sensitive to
Fas-mediated apoptosis [22]. The 293 cells were incubated
for 22 hours with conditioned medium from splenocytes
treated or not treated with activated matrilysin and apop-
tosis was measured by determining the percentage of cells
with fragmented nuclei containing a sub-G1 content of
DNA. Matrilysin-treated splenocytes gave conditioned
medium that demonstrated a reproducible 3.7-fold
increase in apoptosis compared with control medium
(Figure 2a, p < 0.05), corresponding to the increase in the
levels of sFasL (Figure 1b, lane 4). The effect on 293 cells
of conditioned medium from matrilysin-treated splenic
1442 Current Biology Vol 9 No 24
Figure 1
Generation of soluble FasL (sFasL) by matrilysin. (a) Recombinant
human FasL (rhFasL,100 ng) was incubated with varying amounts of
APMA-activated matrilysin with or without 0.5 mM Batimastat for
30 min at 37°C. The reactions were analyzed by western blotting for
the FLAG tag on the rhFasL. The FLAG-tagged fragment was apparent
upon a longer exposure. The amount of intact rhFasL in matrilysin-
treated samples relative to the untreated sample was determined by
densitometry and the percentage remaining is indicated at the bottom
of each lane. The blot shown is representative of two separate
experiments. (b) Activated splenocytes (either wild type (WT) or gld)
were treated for 6 h with increasing concentrations of activated
recombinant matrilysin. The conditioned media (CM) were collected
and filtered before analysis of sFasL by western blotting. The fold
increase of sFasL detected in treated versus untreated splenocytes is
indicated along the bottom. A sample of a total splenocyte lysate is
also included to indicate the relative sizes of the full-length and soluble
forms of FasL. Sizes of molecular weight markers are indicated on the
right-hand side. The blot shown is representative of six experiments. 
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blasts was confirmed to be apoptosis using a DNA ladder-
ing assay (Figure 2b). Direct addition of matrilysin to 293
cells had no effect on apoptosis (Figure 2a). Stimulation of
apoptosis was also observed using HBL100 human breast
epithelial indicator cells (data not shown).
To ensure that the matrilysin-induced increase in apopto-
sis was the result of FasL cleavage, spleen cells from FasL-
defective gld mice were used as a source of sFasL.
Conditioned medium from matrilysin-treated gld cells did
not induce apoptosis (Figure 2a), although comparable
amounts of sFasL were released from these cells and from
wild-type cells following matrilysin treatment (Figure 1b,
compare lanes 4 and 6). In addition, the effect of matrilysin
was abrogated when conditioned medium from matrilysin-
treated wild-type splenocytes was incubated with the
FasL-neutralizing antibody Kay-10 (Figure 2a). Thus, the
effect of matrilysin treatment on activated splenocytes
depended on the generation of active soluble FasL. Condi-
tioned medium from splenocytes that had not been treated
with matrilysin induced only a 1.9-fold increase in apopto-
sis (Figure 2a), which was not significantly different from
the basal apoptotic index in 293 cells. This small increase
might reflect the constitutively released sFasL present in
the conditioned medium (Figure 1b, lane 2) but the more
probable explanation for this induction, given that the
effect is similar whether gld spleen cells or the FasL-neu-
tralizing antibody is used, is the presence in the condi-
tioned media of other death factors.
Matrilysin and FasL are coexpressed in the prostate
We have shown previously that matrilysin mRNA is
induced in epithelial cells in the rat ventral prostate fol-
lowing castration [13]. To determine whether matrilysin
protein is similarly regulated in the mouse dorsal/lateral
(DL) prostate, adult male mice were castrated and pros-
trates were removed at days 2 and 5 post-castration and
examined by immunohistochemistry with an affinity-puri-
fied anti-mouse matrilysin polyclonal antibody. There was
little or no matrilysin protein observed in the DL pros-
trates of intact animals (Figure 3a). By 2 days post-castra-
tion, significant matrilysin production was observed in
individual glands and expression continued for 5 days
after castration (Figure 3d and data not shown). Similarly
to in situ hybridization observations in the rat [13], murine
matrilysin protein was restricted to a subpopulation of
epithelial cells of the prostate (Figure 3d,g). Interestingly,
the matrilysin protein localized to the apical surfaces of
the prostate epithelial cells (Figure 3g), rather than con-
centrating at the basement membrane as would be
expected for a matrix-degrading protease. Apical and
luminal localization of matrilysin has previously been
observed in various human glandular epithelia [23].
FasL and Fas levels were also examined by immunohisto-
chemistry in the involuting mouse prostate. There was little
or no FasL detected in the normal mouse prostate
(Figure 3b), consistent with low levels of FasL in the mouse
prostate reported by French et al. [2]. As observed with
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Figure 2
sFasL is functionally active. (a) Splenocyte
conditioned medium (CM) in the presence of
a FasL-neutralizing antibody or an isotype
control was incubated with 293 cells for 22 h.
The epithelial cells were harvested, fixed and
stained with propidium iodide and then
analyzed by flow cytometry. Peaks
corresponding to populations in G1 and G2
phases of the cell cycle are indicated, as are
the sub-G1 areas. The numbers on each
panel correspond to the mean ± standard
deviation (SD) of the population with
fragmented DNA (sub-G1) obtained from at
least three separate experiments. Statistical
significance was assessed using Student’s
t-test and those samples reaching significance
(p < 0.05) are indicated with an asterisk.
(b) Genomic DNA was isolated from 293
cells which had been exposed to untreated
splenocyte CM (CM) or CM from splenocytes
treated with 100 ng/ml matrilysin (CM + MAT)
and was analyzed by agarose gel
electrophoresis. The characteristic DNA
laddering pattern associated with apoptosis
can be clearly seen in the matrilysin-treated
CM lane. The left-hand lane contains a DNA
size marker. The gel shown is representative
of three separate experiments.
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matrilysin, however, there was a strong induction of FasL in
the epithelium of the prostate 2 days after castration, which
continued through 5 days post-castration (Figure 3e,h and
data not shown). Interestingly, matrilysin and FasL demon-
strated a virtually identical pattern of spatial colocalization
in adjacent sections (Figure 3, compare d and e, g and h). In
contrast to matrilysin and FasL, Fas was present in normal
mouse prostate epithelium at a low constitutive level that
remained unchanged following castration (Figure 3c,f and
data not shown). Fas expression was more widespread that
that of matrilysin or FasL, and all prostate epithelial cells
had detectable Fas immunoreactivity, which also appeared
localized to the apical surface (Figure 3i). Although Fas has
been previously reported to be upregulated in the murine
prostate in response to castration [5], we could detect no dif-
ference in Fas levels by immunohistochemistry following
castration (Figure 3c,f,i).
Matrilysin-null mice demonstrate reduced apoptosis
To determine if matrilysin regulates Fas-mediated prostate
apoptosis, castration-induced apoptosis was compared in
wild-type and matrilysin-deficient mice. Matrilysin-defi-
cient (mmp7–/–) mice previously generated in this laboratory
develop normally and have no obvious reproductive defects,
although alterations in intestinal tumor development and
compensatory increases in other MMP family members
during uterine involution have been observed [24,25]. The
apoptotic index in the DL prostate of wild-type and mmp7–/–
mice was examined at 2 and 5 days post-castration using the
TUNEL assay, which detects fragmented nuclear DNA
(Figure 4a). The lack of matrilysin in the mmp7–/– mice
was confirmed by immunohistochemical analysis of the
involuting prostate and the expression of Fas and FasL
was identical to that observed in wild-type mice (data not
shown). At both 2 and 5 days post-castration, there was a
highly significant 67% reduction (p < 0.001) in the per-
centage of TUNEL-positive epithelial cells in the mmp7–/–
mice compared with wild-type animals (Figure 4b). As
judged by the histological morphology of the DL prostate
in matrilysin-deficient mice after castration, involution
occurred but appeared to be slightly slower than in the
matrilysin wild-type animals (data not shown). Two days
post-castration the mmp7–/– prostrates were larger than
wild type as determined by wet weight analysis, but the
difference did not reach statistical significance. The
reduction in apoptosis caused by the loss of matrilysin
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Figure 3
Immunohistochemical localization of matrilysin, FasL and Fas in
control and castrated mice. Immunohistochemical (IHC) staining 
was performed on dorsal/lateral prostate tissue from control
(a–c) and 2-day castrated (d–i) wild-type mice. IHC staining for
matrilysin (a,d,g), FasL (b,e,h) and Fas (c,f,i) is shown using a blue
substrate to detect HRP and a red nuclear counterstain. The scale
bar represents 50 µm.
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Figure 4
Castration-induced apoptosis in wild-type and matrilysin-deficient
animals. (a) The TUNEL assay was performed on dorsal/lateral
prostate tissue at 2 and 5 days post-castration in wild-type (WT) and
matrilysin-deficient animals (mmp7–/–). An example of the staining seen
at 2 days post-castration in WT and mmp7–/– glands is shown. Arrows
indicate TUNEL-positive cells. (b) Epithelial nuclei (> 3,000 for each
mouse) were counted and the percentage of TUNEL-positive epithelial
cells was determined. There was a statistically significant 67%
reduction in TUNEL-positive cells in the matrilysin-deficient animals at
both 2 and 5 days after castration (two-tailed t-test, *p < 0.001).
n = number of animals in each group. Error bars are ± SD.
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indicates that matrilysin activity contributes to the removal
of epithelial cells during prostate regression. 
Discussion
The MMPs or their endogenous inhibitors have been impli-
cated in apoptotic processes in several systems [26–31]. In
general, this activity is thought to occur as a result of the
breakdown of cell–matrix contacts leading to a form of
apoptosis referred to as anoikis [32,33]. In the involuting
prostate matrilysin is localized to the apical surface of the
cells, however, suggesting that substrates that are also api-
cally localized are more relevant. Apoptosis of the prostate
epithelium has been shown to be dependent on a Fas-medi-
ated pathway. Here we provide evidence that, in contrast to
a role in destroying matrix-mediated survival signals, the
MMP matrilysin can promote apoptosis via the generation
of a biologically active death-inducing protein, sFasL.
The activity of sFasL has been extensively debated in the
literature. There is evidence both in favor of and opposing
its activity. We hypothesize that activity is target-cell spe-
cific. In general, sFasL with little or no activity has been
reported when lymphoid cells have been used as targets,
for example the human T-cell line Jurkat [34] or murine
T-cell lymphoma WR19L and its Fas-expressing transfor-
mant W4 [10,11]. This might be because of an activation-
induced resistance to sFasL as described previously [11].
In contrast, epithelial cell populations, for example
hepatic stellate cells, have been reported to be sensitive to
sFasL-mediated death [35]. We demonstrated that
matrilysin-generated sFasL was effective at inducing
apoptosis in target epithelial cell populations. The same
preparation had no activity when Jurkat T cells were used
as the indicator cells (data not shown). This observation
supports the premise that the apoptosis-inducing activity
of sFasL is dependent on the target cell population.
The MMPs have been implicated as sheddases for biologi-
cally active cell-surface factors or receptors [36,37]. We
demonstrated that matrilysin can cleave recombinant as
well as cellular FasL, supporting the possibility of a direct
proteolytic effect. In a recent phage-display study a
number of excellent peptide substrates for matrilysin were
found, all of which contained the core sequence
Glu–Leu–Arg [38]. Interestingly, this sequence is found in
mouse, rat and human FasL and is highly conserved at a
position close to the transmembrane domain, suggesting
that it might represent the matrilysin-cleavage site.
Although direct cleavage appears probable, we cannot rule
out the possibility that a cascade of enzymes is required for
the generation of sFasL.
Our data indicate that the loss of matrilysin reduces
prostate epithelial cell apoptosis by 67%, but does not com-
pletely abolish the effect of androgen ablation in the
prostate. There are several possible explanations for the
continued low-level apoptosis in the matrilysin-deficient
mice and the final completion of the involution process,
including the presence of other proteases that might also
cleave FasL to its soluble form. We have preliminary evi-
dence that the MMPs gelatinase A, gelatinase B and
stromelysin-1 are not capable of releasing sFasL (data not
shown). Other metalloproteinases, particularly those
similar to the TNF-α sheddase TACE, are possible candi-
dates, however. We also cannot rule out the possibility that
the induction of precursor FasL is sufficient to initiate
some interactions with Fas at the cell surface, bypassing
the need for FasL cleavage. Finally, redundant pathways
for apoptosis induced by androgen withdrawal are also pos-
sible. For example, incomplete elimination of apoptotic
bodies in the involuting prostrates of p53-deficient mice
demonstrates that both p53-dependent and independent
mechanisms of apoptosis exist in this system [39].
Fas-mediated apoptosis is well studied as a mechanism for
selective removal of T cells following an immune
response. Recently, the expression of Fas and FasL was
examined in a number of non-lymphoid tissues [2,3]. Fas
was expressed in almost all tissues examined, whereas
FasL expression was much more restricted. Interestingly,
both of these studies identified a number of normal
tissues that express both Fas and FasL, including lung,
intestine, seminal vesicle and prostate. This colocalization
suggests that either Fas and FasL are expressed by differ-
ent cell types within the same tissue, or that coexpression
of FasL and Fas on the same cell does not initiate apopto-
sis in the absence of other signals. One possibility is that
effective FasL–Fas interactions on the same cell type are
dependent on the production of soluble FasL. This might
be particularly important for epithelial cells, which are
attached to a basement membrane and sort membrane
components into distinct compartments. In the glandular
epithelium of the prostate, the transmembrane proteins
Fas and FasL are both apically localized. Although lateral
interactions are possible, complete interaction between
their extracellular domains would presumably be con-
strained by transmembrane anchoring. Our results suggest
that the production of an epithelium-specific processing
enzyme such as matrilysin might be necessary to initiate
an apoptotic signaling pathway in solid tissues.
Materials and methods
Animals
The generation of matrilysin-null mice was described previously [24].
Outbred (Sv129 × C57/Bl6) mice homozygous for the mmp7m1Vu or
wild-type mmp7 alleles were used for all castration studies. Ten-week-
old male mice were anesthetized and castrated via the abdominal
route. The animals were killed 2 and 5 days after castration and the
dorsal/lateral prostate was removed, fixed in 4% paraformaldehyde
overnight and paraffin embedded. 
Cleavage of FasL
Purified recombinant human soluble FasL (entire extracellular region
attached to a FLAG tag) was obtained from Alexis Biochemicals (San
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Diego, CA) and the purified human matrilysin was a generous gift from
Harold VanWart (Roche Biosciences Inc., Palo Alto, CA) [40]. The
matrilysin protein was activated by treatment with 1 µM pAminophenyl
mercuric acetate (APMA) for 1 h at 37°C. The indicated amounts of
FasL and activated matrilysin were added to 30 µl MMP buffer (50 mM
Tris pH 7.4; 10 mM CaCl2) and incubated at 37°C for 30 min. The MMP
inhibitor Batimastat was a generous gift from Peter Brown (British
Biotech, Oxford, UK) and was added at a concentration of 0.5 mM.
Freshly isolated spleens from C57/Bl6 mice were macerated, the cells
suspended in RPMI 1640 medium (Gibco-BRL) and centrifuged to
remove debris. Splenocytes were isolated following removal of red blood
cells by hydrolysis and rinsing in PBS and RPMI 1640 and were resus-
pended in RPMI 1640 supplemented with 10% FCS (Atlanta Biologi-
cals). Activation was achieved by incubation with 100 µg/ml concanavalin
A (Sigma) and 5 ng/ml IL-2 (Gibco-BRL) at 37°C for 8 h. The con-
canavalin A was removed by treatment with 100 µg/ml α-methyl-manno-
side (Sigma) for 20 min at 37°C before rinsing in serum-free medium. The
cells were resuspended at a concentration of 5 × 106 cells/ml in serum-
free medium and treated with the indicated concentrations of activated
recombinant matrilysin (Chemicon) for 6 h. The conditioned media were
collected and clarified by centrifugation and filtration through a 0.2 µm
filter (Corning) to remove cellular material. 
Western analysis
Samples were subjected to SDS–PAGE in a 15% gel then elec-
trophoretically transferred to nitrocellulose. The blots were blocked with
5% non-fat dry milk in Tris-buffered saline pH 7.4 and the primary anti-
bodies were added in fresh blocking solution. The anti-FLAG M2 (Kodak)
and anti-FasL (Transduction Laboratories) antibodies were used at a dilu-
tion of 1:1000. For the FLAG western, a horseradish peroxidase (HRP)-
conjugated secondary antibody (Promega) and chemiluminescent
detection (p-coumaric acid (Sigma), 200 µM; luminol (Sigma), 1.25 mM;
100 mM Tris base pH 8.5) was used to visualize the immunoreactive
bands. For the FasL western, a biotinylated secondary antibody (Vector
Labs) and HRP-labeled streptavidin (Jackson ImmunoResearch) were
used for detection and the bands were visualized using enhanced chemi-
luminesence (Amersham).
Immunohistochemistry
The paraffin-embedded tissue was cut in 5 µm sections onto glass
slides, deparaffinized in xylene and rehydrated. Immunohistochemical
staining was performed following microwave antigen retrieval (3 min,
high power in 100 mM sodium citrate pH 6.0). The primary antibodies
were detected with biotinylated secondary antibodies and ABC amplifi-
cation (Vector Labs). The HRP-labeled immune complex was detected
using the substrate True Blue (KPL Laboratories) and counterstained
with Contrast Red (KPL Laboratories). Photographs were taken using a
Zeiss photomicroscope and a CCD camera. The primary antibodies
used were: affinity-purified rabbit polyclonal anti-mouse matrilysin
(1:5,000) [24], affinity-purified rabbit polyclonal anti-FasL C-178
(1:1,000, Santa Cruz) and affinity-purified rabbit polyclonal anti-Fas
M-20 (1:1,000, Santa Cruz).
Apoptosis assays
The 293 cells were grown in DMEM (Gibco-BRL) supplemented with
10% FCS and were plated at a concentration of 1 × 106 cells per well
of a six-well cell culture dish one day before conditioned medium trans-
fer. The conditioned medium was transferred to monolayers of 293 cells
from which the growth medium had been removed, and incubated for
22 h. This incubation was performed in the presence of 2 µg/ml of the
FasL-neutralizing antibody, Kay-10 (Pharmingen) or of an isotype control
(Pharmingen). The cells were harvested for analysis of apoptosis by cen-
trifugation and rinsing in PBS. Cell pellets were resuspended in 300 µl
of PBS to which was added 700 µl of 100% ethanol. The cells were
pelleted and resuspended in PBS containing 50 µg/ml RNase A for
30 min at room temperature. Propidium iodide was then added to a final
concentration of 50 µg/ml and the samples analyzed by flow cytometry
using a FACStar. Data analysis was performed using the software
package FlowJo (Treister Enterprises). As a positive control, cells were
incubated with 0.5 µg/ml of the CH11 Fas-activating antibody (Upstate
Biologicals) resulting in a threefold increase in the sub-G1 peak.
For DNA laddering analysis, monolayers of 293 cells grown on 60 mm
dishes were exposed to treated or untreated splenocyte conditioned
medium for 22 h and the cells harvested by scraping and centrifuging.
They were washed once in PBS and lysed in laddering lysis buffer (1%
NP-40, 20 mM EDTA, 50 mM Tris pH 7.5). The supernatants were
RNase-treated at 37°C for 2 h and then digested with proteinase K
overnight at 55°C. The DNA was precipitated with ammonium acetate
and ethanol and then resuspended in Tris-EDTA pH 8.0. Samples were
normalized for DNA content, run on a 1.7% agarose gel and visualized
following ethidium bromide staining.
For TUNEL analysis, 5 µm sections were rehydrated and incubated with
terminal deoxytransferase (TdT) (0.25 U/µl) and biotin-dUTP (0.4 nM/ml)
in 1 × TdT buffer (Boehringer Mannheim) for 1 h. The slides were washed
and blocked with 1% goat serum and incubated with HRP-conjugated
streptavidin. HRP was detected using diaminobenzidine and the slides
were counterstained with methyl green. Random areas of sections from
the indicated number of wild-type or matrilysin-null animals were scored
for the number of apoptotic epithelial cell nuclei per 3,000 total epithelial
cell nuclei without knowledge of sample identity. The two-sample t-test
was used to determine the statistical significance of the data.
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